Cargando…

Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines

HER2 is overexpressed in 25–30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuroiwa, Yuka, Nakayama, Jun, Adachi, Chihiro, Inoue, Takafumi, Watanabe, Shinya, Semba, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408688/
https://www.ncbi.nlm.nih.gov/pubmed/32640677
http://dx.doi.org/10.3390/cancers12071811
_version_ 1783567889351049216
author Kuroiwa, Yuka
Nakayama, Jun
Adachi, Chihiro
Inoue, Takafumi
Watanabe, Shinya
Semba, Kentaro
author_facet Kuroiwa, Yuka
Nakayama, Jun
Adachi, Chihiro
Inoue, Takafumi
Watanabe, Shinya
Semba, Kentaro
author_sort Kuroiwa, Yuka
collection PubMed
description HER2 is overexpressed in 25–30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype, and the molecular mechanisms of brain metastasis in HER2-positive breast cancer are unclear. In the present study, we performed intracranial injection using nine HER2-positive breast cancer cell lines to evaluate their proliferative activity in brain tissue. Our results show that UACC-893 and MDA-MB-453 cells rapidly proliferated in the brain parenchyma, while the other seven cell lines moderately or slowly proliferated. Among these nine cell lines, the proliferative activity in brain tissue was not correlated with either the HER2 level or the HER2 phosphorylation status. To extract signature genes associated with brain colonization, we conducted microarray analysis and found that these two cell lines shared 138 gene expression patterns. Moreover, some of these genes were correlated with poor prognosis in HER2-positive breast cancer patients. Our findings might be helpful for further studying brain metastasis in HER2-positive breast cancer.
format Online
Article
Text
id pubmed-7408688
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74086882020-08-13 Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines Kuroiwa, Yuka Nakayama, Jun Adachi, Chihiro Inoue, Takafumi Watanabe, Shinya Semba, Kentaro Cancers (Basel) Article HER2 is overexpressed in 25–30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype, and the molecular mechanisms of brain metastasis in HER2-positive breast cancer are unclear. In the present study, we performed intracranial injection using nine HER2-positive breast cancer cell lines to evaluate their proliferative activity in brain tissue. Our results show that UACC-893 and MDA-MB-453 cells rapidly proliferated in the brain parenchyma, while the other seven cell lines moderately or slowly proliferated. Among these nine cell lines, the proliferative activity in brain tissue was not correlated with either the HER2 level or the HER2 phosphorylation status. To extract signature genes associated with brain colonization, we conducted microarray analysis and found that these two cell lines shared 138 gene expression patterns. Moreover, some of these genes were correlated with poor prognosis in HER2-positive breast cancer patients. Our findings might be helpful for further studying brain metastasis in HER2-positive breast cancer. MDPI 2020-07-06 /pmc/articles/PMC7408688/ /pubmed/32640677 http://dx.doi.org/10.3390/cancers12071811 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuroiwa, Yuka
Nakayama, Jun
Adachi, Chihiro
Inoue, Takafumi
Watanabe, Shinya
Semba, Kentaro
Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
title Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
title_full Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
title_fullStr Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
title_full_unstemmed Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
title_short Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
title_sort proliferative classification of intracranially injected her2-positive breast cancer cell lines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408688/
https://www.ncbi.nlm.nih.gov/pubmed/32640677
http://dx.doi.org/10.3390/cancers12071811
work_keys_str_mv AT kuroiwayuka proliferativeclassificationofintracraniallyinjectedher2positivebreastcancercelllines
AT nakayamajun proliferativeclassificationofintracraniallyinjectedher2positivebreastcancercelllines
AT adachichihiro proliferativeclassificationofintracraniallyinjectedher2positivebreastcancercelllines
AT inouetakafumi proliferativeclassificationofintracraniallyinjectedher2positivebreastcancercelllines
AT watanabeshinya proliferativeclassificationofintracraniallyinjectedher2positivebreastcancercelllines
AT sembakentaro proliferativeclassificationofintracraniallyinjectedher2positivebreastcancercelllines